This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shah, P. K Search for Related Content PubMed PubMed Citation Articles by Shah, P. K Social Bookmarking                   What's this?

Role of inflammation and metalloproteinases in plaque disruption and thrombosis

Atherosclerosis Research Center, Division of Cardiology, Burn and Allen Research Institute and Department of Medicine, Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, USA

Numerous pathological, clinical, angiographic and angioscopic studies have demonstrated that acute coronary syndromes (unstable angina, acute myocardial infarction and ischemic sudden death) are most frequently the consequence of plaque disruption (plaque rupture or superficial plaque erosion) and consequent coronary thrombosis. Several serial angiographic studies have demonstrated that nearly 60-70% of acute coronary syndromes evolve from mildly to moderately obstructive atherosclerotic plaques. Coronary plaque disruption appears to be a function of both the composition of the plaque (plaque vulnerability) as well as extrinsic triggers that may precipitate plaque disruption in a vulnerable plaque. Vulnerability for plaque disruption appears to be largely determined by the size of the lipid-rich atheromatous core, the thickness of the fibrous cap covering the core, and the presence of ongoing inflammation within and underneath the cap. inflammatory cells may play a critical role in plaque disruption through the elaboration of matrix degrading metalloproteinases or MMPs (collagenases, gelatinases, stromelysins and matrilysin) and by inhibition of function and survival of matrix-synthesizing smooth muscle cells. inflammatory cells may also play a critical role in triggering thrombosis following plaque disruption through the tissue factor pathway. In addition, stresses resulting from hemodynamic and mechanical forces may precipitate plaque disruption, particularly at points where the fibrous cap is weakest, such as at its shoulders. The degree of thrombosis following plaque disruption is determined by the thrombogenicity of the disrupted plaque, disturbed local rheology and systemic thrombotic-thrombolytic milieu. Surges in sympathetic activity provoked by sudden vigorous exercise, emotional stress -including anger, or cold weather, may also trigger plaque disruption. These observations have led to the concept of plaque stabilization as a new clinical strategy for the prevention of acute coronary syndromes. Plaque stabilization can be achieved through pharmacologic and lifestyle-modifying interventions that reduce vulnerability to plaque disruption by altering plaque composition and/or inflammatory activity within the plaque.

Key Words: inflammation • metalloproteinases • plaque disruption • thrombosis

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Z Szekanecz and Y Shoenfeld Lupus and cardiovascular disease: the facts Lupus, November 1, 2006; 15(11_suppl): 3 - 10. [Abstract] [PDF]

				L. Nilsson, L. Jonasson, J. Nijm, A. Hamsten, and P. Eriksson Increased Plasma Concentration of Matrix Metalloproteinase-7 in Patients with Coronary Artery Disease Clin. Chem., August 1, 2006; 52(8): 1522 - 1527. [Abstract] [Full Text] [PDF]

				R. de Nooijer, C.J.N. Verkleij, J.H. von der Thusen, J.W. Jukema, E.E. van der Wall, Th. J.C. van Berkel, A.H. Baker, and E.A.L. Biessen Lesional Overexpression of Matrix Metalloproteinase-9 Promotes Intraplaque Hemorrhage in Advanced Lesions But Not at Earlier Stages of Atherogenesis Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 340 - 346. [Abstract] [Full Text] [PDF]

				S. Agewall Matrix metalloproteinases and cardiovascular disease Eur. Heart J., January 2, 2006; 27(2): 121 - 122. [Full Text] [PDF]

				J. Mikkelsson, M. Perola, and P. J. Karhunen Genetics of Platelet Glycoprotein Receptors: Risk of Thrombotic Events and Pharmacogenetic Implications Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 113 - 125. [Abstract] [PDF]

				B. Burke, A. Giannoudis, K. P. Corke, D. Gill, M. Wells, L. Ziegler-Heitbrock, and C. E. Lewis Hypoxia-Induced Gene Expression in Human Macrophages: Implications for Ischemic Tissues and Hypoxia-Regulated Gene Therapy Am. J. Pathol., October 1, 2003; 163(4): 1233 - 1243. [Abstract] [Full Text] [PDF]

				P. K. Shah Mechanisms of plaque vulnerability and rupture J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 15S - 22S. [Abstract] [Full Text] [PDF]

				M. Naghavi, P. Wyde, S. Litovsky, M. Madjid, A. Akhtar, S. Naguib, M. S. Siadaty, S. Sanati, and W. Casscells Influenza Infection Exerts Prominent Inflammatory and Thrombotic Effects on the Atherosclerotic Plaques of Apolipoprotein E-Deficient Mice Circulation, February 11, 2003; 107(5): 762 - 768. [Abstract] [Full Text] [PDF]

				P. K. Shah and Z. S. Galis Matrix Metalloproteinase Hypothesis of Plaque Rupture: Players Keep Piling Up But Questions Remain Circulation, October 16, 2001; 104(16): 1878 - 1880. [Full Text] [PDF]

				U. E. Heidland and B. E. Strauer Left Ventricular Muscle Mass and Elevated Heart Rate Are Associated With Coronary Plaque Disruption Circulation, September 25, 2001; 104(13): 1477 - 1482. [Abstract] [Full Text] [PDF]

				M. Crisby, G. Nordin-Fredriksson, P. K. Shah, J. Yano, J. Zhu, and J. Nilsson Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques : Implications for Plaque Stabilization Circulation, February 20, 2001; 103(7): 926 - 933. [Abstract] [Full Text] [PDF]

				A. W. Haider, M. Luna, S. Patel, J. M. Gaziano, L. Glenn, L. M. Golub, R. A. Greenwald, R. W. Thompson, D. L. Hahn, M. R. Hammerschlag, et al. Antibiotic Use and Risk of Myocardial Infarction JAMA, December 1, 1999; 282(21): 1997 - 1999. [Full Text] [PDF]